Five Strategies to Optimize Your Specialty Pharmacy Program

SPONSORED CONTENT

While specialty drugs were used by less than 2% of the population in 2020, “they accounted for almost 51% of spending under the pharmacy benefit.”[1] Within your 340B program, these numbers can be even higher. On average, we see about six percent of volume resulting in close to fifty percent of savings for our clients. With numbers like this, it’s imperative to understand how to manage your 340B specialty contract pharmacies in order to maximize program value.

Below are five strategies to optimize your specialty pharmacy program:

1. Register your “ology’s”

There are six types of eligible clinics within a health system typically driving the majority of specialty value:  dermatology, gastroenterology, rheumatology, endocrinology, neurology, and oncology. Medications dispensed through these clinics have high utilization and yield high savings. Ensuring these clinics are eligible and registered is the first, and most important strategy when capturing specialty value.

2. Set up your ideal specialty network

When developing a specialty network tailored to

Read More »

Lilly and Feds Disagree Over Whether 340B Case Is Ripe for Appeal

Drug maker Lilly and the federal government disagree over Lilly's 340B contract pharmacy appeal to U.S. Seventh Circuit Court of Appeals.

Drug manufacturer Lilly and the federal government disagree over whether a federal district judge’s recent decision in Lilly’s 340B contract pharmacy case is ripe for review.

Last month, the U.S. Seventh Circuit Court of Appeals questioned whether U.S. Senior

Read More »

Supreme Court May Upend Medicare DSH Calculation Formula, Which Would Impact 340B Stakeholders

The U.S. Supreme Court heard a case this week about the Medicare disproportionate share (DSH) adjustment percentage calculation—a 340B eligibility criterion for hospitals.

340B hospitals’ challenge to Medicare Part B drug reimbursement cuts was not the only case on the U.S. Supreme Court docket this week that could have a significant impact on the program.

On Monday, the justices heard the case of

Read More »

Breaking News

Breaking News: Amgen Announces 340B Contract Pharmacy Limits for Hospitals

Amgen this morning became the 10th pharmaceutical manufacturer to announce conditions on 340B pricing when contract pharmacies dispense medicines to patients.

UPDATED Wednesday Dec. 1, 2021, 1:15 p.m. EST—Includes comments from Amgen, HRSA, and hospital group 340B Health.

Biopharmaceutical manufacturer Amgen this morning became the 10th pharmaceutical company to announce conditions on 340B pricing when contract pharmacies dispense medicines to

Read More »

News Alert: U.S. Supreme Court Justices Question CMS’s Legal Basis for Slashing 340B Hospitals’ Drug Reimbursement

The U.S. Supreme Court heard arguments today about the legality of the nearly 30% Medicare Part B drug payment cut for 340B hospitals.

Several U.S. Supreme Court justices asked during a hearing today whether the Centers for Medicare & Medicaid Services (CMS) had statutory authority to single out 340B hospitals for a nearly 30% cut in Medicare Part B drug reimbursement beginning in

Read More »

340B Providers Take Center Stage Before U.S. Supreme Court Today

The U.S. Supreme Court is hearing arguments this morning in a lawsuit challenging CMS's nearly 30% cut in 340B hospitals' drug reimbursement.

The U.S. Supreme Court is hearing arguments this morning in a lawsuit challenging the nearly 30% cut since 2018 in what Medicare Part B pays hospitals for 340B-purchased physician administered drugs.

Arguments in American Hospital Association v. Becerra are due

Read More »

Clovis Oncology Reverses Decision to Use Kalderos’ 340B Pricing-as-Rebate System

Clovis Oncology has decided for now not to implement Kalderos’ 340B Pay service to pay 340B ceiling prices as rebates instead of as discounts.

Drug manufacturer Clovis Oncology has decided for now not to implement drug discount management company Kalderos’ 340B Pay service to let drug companies pay 340B ceiling prices as back-end rebates instead of as front-end discounts, Kalderos said late yesterday.

“We

Read More »

U.S. House GOP Conference Chair Stefanik Backs Protecting 340B Hospitals from Losing Eligibility During Pandemic

U.S. House GOP Conference Chair Elise Stefanik (N.Y.) is backing a bill to protect hospitals from losing their 340B eligibility due to pandemic-related changes in patient and payer mix.

Elise Stefanik, the third highest-ranking Republican in the U.S. House, is backing a bill to protect hospitals from losing their 340B eligibility due to pandemic-related changes in patient and payer mix.

Stefanik (R-N.Y.) announced her co-sponsorship of Reps. Doris

Read More »

Peter Welch, Long-Time 340B Advocate in the U.S. House, Announces Run for Senate

U.S. Rep. Peter Welch (D-Vt.), a long-time 340B advocate, is running for the U.S. Senate next year.

U.S. Rep. Peter Welch (D-Vt.), who has backed 340B covered entities in several policy battles, is running to succeed his fellow Democrat Patrick Leahy in the U.S. Senate.

Senate President Pro Tempore Leahy, 81, announced on Nov. 15 that he

Read More »

UCB Becomes Ninth Drug Manufacturer to Announce 340B Contract Pharmacy Limits

Belgian-based UCB is the ninth drug company to impose limits on 340B pricing involving contract pharmacies.

Belgian-based pharmaceutical manufacturer UCB this morning became the ninth drug company to impose limits on 340B pricing involving contract pharmacies.

Hospitals reported getting letters and an FAQ from UCB today by email announcing that, effective Dec. 13 and with

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report